Crossref
Lecanemab Gains FDA Approval for Early Alzheimer Disease
JAMA · 2023
DOI: 10.1001/jama.2022.24490 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Howard D Larkin. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Approval, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 48-mal zitiert (Crossref).
Themen: Demenz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Alzheimer DiseaseDrug ApprovalAntibodies, Monoclonal, HumanizedHumansUnited StatesUnited States Food and Drug Administration
Substanzen
lecanemabAntibodies, Monoclonal, Humanized
Zitieren
APA
Larkin, H. D. (2023). Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA. https://doi.org/10.1001/jama.2022.24490
Vancouver
Larkin HD. Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA. 2023. doi:10.1001/jama.2022.24490
BibTeX
@article{Larkin2023,
author = {Larkin, Howard D},
title = {Lecanemab Gains FDA Approval for Early Alzheimer Disease},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2022.24490}
}
EUVIMED